Alumis (ALMS)
Alumis on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
10.3M
Short interest
settlement 2026-09-30
3.6
Days to cover
+2.6 days vs prior
41.1%
Short share of volume
2026-10-09
291,588
Fails to deliver
settlement 2026-09-08
Thu 12 Nov
Next earnings
estimated date
$9.3M
Insider flow, 90 days
4 buys, 8 sells
As of 2026-10-09.
Short interest
FINRA, twice a month. The newest 24 settlements in the table, 48 in the chart. JSONAs of 30 September 2026, short interest in ALMS is 10,295,705 shares, up 4,649,952 shares over the last month. Over the last 48 readings it ranged from 1,853,671 shares (15 August 2025) to 14,294,503 shares (30 June 2026). At the reported average volume of 2.9M shares a day that is 3.6 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/alms" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-09-30 | 10,295,705 | +63.5% | 2,869,547 | 3.59 |
| 2026-09-15 | 6,299,106 | +11.6% | 7,177,824 | 1.00 |
| 2026-08-31 | 5,645,753 | -3.6% | 798,956 | 7.07 |
| 2026-08-14 | 5,853,901 | +1.5% | 897,557 | 6.52 |
| 2026-07-31 | 5,766,070 | -14.8% | 943,099 | 6.11 |
| 2026-07-15 | 6,764,417 | -52.7% | 1,774,538 | 3.81 |
| 2026-06-30 | 14,294,503 | +12.9% | 1,889,883 | 7.56 |
| 2026-06-15 | 12,658,548 | +14.3% | 1,454,605 | 8.70 |
| 2026-05-29 | 11,072,158 | -2.5% | 853,938 | 12.97 |
| 2026-05-15 | 11,359,303 | +0.6% | 806,691 | 14.08 |
| 2026-04-30 | 11,287,439 | -7.6% | 1,252,290 | 9.01 |
| 2026-04-15 | 12,210,305 | +8.7% | 1,247,290 | 9.79 |
| 2026-03-31 | 11,230,693 | +25.3% | 2,042,725 | 5.50 |
| 2026-03-13 | 8,963,277 | +12.7% | 1,205,239 | 7.44 |
| 2026-02-27 | 7,953,241 | -12.2% | 1,322,625 | 6.01 |
| 2026-02-13 | 9,054,577 | +4.4% | 1,187,237 | 7.63 |
| 2026-01-30 | 8,670,302 | -0.0% | 1,954,807 | 4.44 |
| 2026-01-15 | 8,672,088 | +93.0% | 10,417,053 | 1.00 |
| 2025-12-31 | 4,492,125 | +15.9% | 951,952 | 4.72 |
| 2025-12-15 | 3,874,655 | +9.6% | 1,455,119 | 2.66 |
| 2025-11-28 | 3,533,932 | +0.1% | 1,323,306 | 2.67 |
| 2025-11-14 | 3,531,192 | +25.6% | 1,029,523 | 3.43 |
| 2025-10-31 | 2,812,394 | +33.3% | 471,886 | 5.96 |
| 2025-10-15 | 2,110,101 | -25.9% | 766,552 | 2.75 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 9 October 2026, the short share of ALMS volume is 41.1%, up 0.1 points over the last five sessions. Over the last 30 readings it ranged from 15.1% (11 September 2026) to 70.6% (31 August 2026). The latest reading is 4.0 points above the 30-session average of 37.1%, on 404K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-09 | 166K | 404K | 41.1% | 0 |
| 2026-10-08 | 219K | 772K | 28.4% | 11 |
| 2026-10-07 | 188K | 649K | 28.9% | 2,119 |
| 2026-10-06 | 197K | 663K | 29.7% | 1,427 |
| 2026-10-05 | 543K | 974K | 55.7% | 0 |
| 2026-10-02 | 381K | 926K | 41.1% | 1,052 |
| 2026-10-01 | 262K | 710K | 36.8% | 200 |
| 2026-09-30 | 208K | 456K | 45.5% | 0 |
| 2026-09-29 | 223K | 508K | 43.9% | 0 |
| 2026-09-28 | 301K | 883K | 34.0% | 22 |
| 2026-09-25 | 305K | 710K | 42.9% | 0 |
| 2026-09-24 | 371K | 915K | 40.5% | 0 |
| 2026-09-23 | 379K | 934K | 40.6% | 0 |
| 2026-09-22 | 363K | 759K | 47.8% | 0 |
| 2026-09-21 | 419K | 920K | 45.6% | 0 |
| 2026-09-18 | 290K | 1.1M | 27.1% | 0 |
| 2026-09-17 | 722K | 1.6M | 46.2% | 0 |
| 2026-09-16 | 313K | 1.7M | 18.1% | 11 |
| 2026-09-15 | 815K | 1.9M | 43.7% | 7,809 |
| 2026-09-14 | 292K | 1.4M | 20.8% | 6,679 |
| 2026-09-11 | 225K | 1.5M | 15.1% | 1,500 |
| 2026-09-10 | 676K | 2.1M | 32.1% | 5,176 |
| 2026-09-09 | 487K | 1.9M | 26.2% | 1,300 |
| 2026-09-08 | 645K | 2.1M | 31.0% | 0 |
| 2026-09-04 | 392K | 1.2M | 31.4% | 1,886 |
| 2026-09-03 | 750K | 3.0M | 24.6% | 0 |
| 2026-09-02 | 880K | 4.2M | 20.8% | 68,217 |
| 2026-09-01 | 4.9M | 13.3M | 37.1% | 684,348 |
| 2026-08-31 | 347K | 492K | 70.6% | 71,344 |
| 2026-08-28 | 148K | 227K | 65.4% | 35,822 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 8 September 2026, the fails-to-deliver balance in ALMS is 291,588 shares, down 99,157 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (23 June 2026) to 390,745 shares (2 September 2026).
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-08 | 291,588 | $11.10 | $3.2M |
| 2026-09-02 | 390,745 | $9.47 | $3.7M |
| 2026-08-11 | 24 | $27.53 | $661 |
| 2026-07-17 | 1 | $27.23 | $27 |
| 2026-07-14 | 3 | $28.10 | $84 |
| 2026-07-02 | 9,494 | $26.64 | $253K |
| 2026-07-01 | 124,360 | $28.14 | $3.5M |
| 2026-06-30 | 3 | $27.14 | $81 |
| 2026-06-29 | 10,546 | $26.40 | $278K |
| 2026-06-25 | 2 | $24.85 | $50 |
| 2026-06-24 | 7 | $24.51 | $172 |
| 2026-06-23 | 1 | $24.60 | $25 |
| 2026-06-15 | 302 | $24.15 | $7K |
| 2026-06-11 | 3 | $20.06 | $60 |
| 2026-06-10 | 48 | $20.01 | $960 |
| 2026-05-22 | 40,000 | $22.17 | $887K |
| 2026-05-19 | 100 | $21.15 | $2K |
| 2026-05-14 | 2,347 | $24.86 | $58K |
| 2026-05-04 | 7 | $25.18 | $176 |
| 2026-04-24 | 375 | $25.99 | $10K |
| 2026-04-20 | 9,858 | $24.99 | $246K |
| 2026-03-30 | 140 | $24.80 | $3K |
| 2026-03-25 | 40 | $23.07 | $923 |
| 2026-03-24 | 23 | $23.36 | $537 |
| 2026-03-09 | 82 | $26.90 | $2K |
| 2026-03-04 | 77 | $28.15 | $2K |
| 2026-02-27 | 823 | $29.98 | $25K |
| 2026-02-20 | 128 | $29.21 | $4K |
| 2026-02-13 | 23,629 | $26.80 | $633K |
| 2026-02-06 | 212 | $26.34 | $6K |
Insider trades
SEC Form 4, newest first, 50 of 100 shown. JSONOver the last 90 days ALMS insiders reported 4 open-market buys ($10.7M) against 8 sells ($1.4M), so the dollar flow leans toward buying. Latest filing: AKKARAJU SRINIVAS (Director) on 2026-09-08.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-08 | AKKARAJU SRINIVAS | Director | Buy | 273K | $10.63 | $2.9M | 2.3M |
| 2026-09-08 | AKKARAJU SRINIVAS | Director | Buy | 273K | $10.63 | $2.9M | 4.9M |
| 2026-09-08 | AKKARAJU SRINIVAS | Director | Sell | 48K | $10.55 | $507K | 2.0M |
| 2026-09-08 | AKKARAJU SRINIVAS | Director | Sell | 48K | $10.55 | $507K | 4.7M |
| 2026-09-04 | AKKARAJU SRINIVAS | Director | Buy | 220K | $11.17 | $2.5M | 2.1M |
| 2026-09-04 | AKKARAJU SRINIVAS | Director | Buy | 220K | $11.17 | $2.5M | 4.7M |
| 2026-08-03 | Pangali Sanam | Chief Legal Officer | Sell | 1K | $26.37 | $36K | 10K |
| 2026-08-03 | Bradley Mark Christopher | Chief Development Officer | Sell | 3K | $26.37 | $68K | 49K |
| 2026-08-03 | Drappa Jorn | Chief Medical Officer | Sell | 2K | $26.37 | $65K | 57K |
| 2026-08-03 | Goldstein David M | Chief Scientific Officer | Sell | 3K | $26.37 | $68K | 31K |
| 2026-08-03 | Schroer John R. | Chief Financial Officer | Sell | 3K | $26.37 | $87K | 25K |
| 2026-08-03 | Hardiman Roy C. | Chief Business & Strategy Ofcr | Sell | 3K | $26.37 | $71K | 208K |
| 2026-07-06 | Pangali Sanam | Chief Legal Officer | Sell | 5K | $28.00 | $140K | 11K |
| 2026-07-06 | Pangali Sanam | Chief Legal Officer | Option exercise | 5K | $5.06 | $25K | 16K |
| 2026-06-30 | TETRAULT LYNN A. | Director | Grant | 4K | $0.00 | $0 | 4K |
| 2026-06-30 | Srivastava Sapna | Director | Grant | 4K | $0.00 | $0 | 4K |
| 2026-06-30 | Yao Zhengbin | Director | Grant | 4K | $0.00 | $0 | 27K |
| 2026-06-30 | Machado Patrick | Director | Grant | 4K | $0.00 | $0 | 4K |
| 2026-06-30 | AKKARAJU SRINIVAS | Director | Grant | 4K | $0.00 | $0 | 4K |
| 2026-05-22 | Drappa Jorn | Chief Medical Officer | Option exercise | 16K | $5.06 | $79K | 59K |
| 2026-05-22 | Drappa Jorn | Chief Medical Officer | Option exercise | 11K | $8.84 | $100K | 44K |
| 2026-04-01 | Foresite Capital Management VI LLC | 10% owner | J | 1.1M | $0.00 | $0 | 0 |
| 2026-04-01 | Tananbaum James B. | Director, 10% owner | J | 1.1M | $0.00 | $0 | 0 |
| 2026-04-01 | Foresite Labs Affiliates 2021, LLC | TenPercentOwner | J | 1.2M | $0.00 | $0 | 0 |
| 2026-04-01 | Foresite Labs Affiliates 2021, LLC | TenPercentOwner | J | 680K | $0.00 | $0 | 680K |
| 2026-04-01 | Foresite Labs Affiliates 2021, LLC | TenPercentOwner | J | 1.1M | $0.00 | $0 | 1.1M |
| 2026-04-01 | Foresite Labs, LLC | 10% owner | J | 680K | $0.00 | $0 | 680K |
| 2026-04-01 | Foresite Labs, LLC | 10% owner | J | 1.1M | $0.00 | $0 | 1.1M |
| 2026-04-01 | Foresite Labs, LLC | 10% owner | J | 1.2M | $0.00 | $0 | 0 |
| 2026-04-01 | Foresite Capital Management VI LLC | 10% owner | J | 680K | $0.00 | $0 | 680K |
| 2026-04-01 | Foresite Capital Management VI LLC | 10% owner | J | 1.1M | $0.00 | $0 | 1.1M |
| 2026-04-01 | Foresite Capital Management VI LLC | 10% owner | J | 1.2M | $0.00 | $0 | 0 |
| 2026-04-01 | Tananbaum James B. | Director, 10% owner | J | 680K | $0.00 | $0 | 680K |
| 2026-04-01 | Tananbaum James B. | Director, 10% owner | J | 1.1M | $0.00 | $0 | 1.1M |
| 2026-04-01 | Tananbaum James B. | Director, 10% owner | J | 1.2M | $0.00 | $0 | 0 |
| 2026-01-09 | AKKARAJU SRINIVAS | Director | Buy | 588K | $17.00 | $10.0M | 1.9M |
| 2026-01-08 | Foresite Labs Fund I, L.P. | TenPercentOwner | Buy | 294K | $17.00 | $5.0M | 2.9M |
| 2026-01-08 | Foresite Labs Fund I, L.P. | TenPercentOwner | Buy | 118K | $17.00 | $2.0M | 5.7M |
| 2026-01-08 | Foresite Labs, LLC | 10% owner | Buy | 294K | $17.00 | $5.0M | 2.9M |
| 2026-01-08 | Foresite Labs, LLC | 10% owner | Buy | 118K | $17.00 | $2.0M | 5.7M |
| 2026-01-08 | Foresite Capital Management VI LLC | 10% owner | Buy | 294K | $17.00 | $5.0M | 2.9M |
| 2026-01-08 | Foresite Capital Management VI LLC | 10% owner | Buy | 118K | $17.00 | $2.0M | 5.7M |
| 2026-01-08 | Tananbaum James B. | Director, 10% owner | Buy | 294K | $17.00 | $5.0M | 2.9M |
| 2026-01-08 | Tananbaum James B. | Director, 10% owner | Buy | 118K | $17.00 | $2.0M | 5.7M |
| 2025-12-05 | AKKARAJU SRINIVAS | Director | Buy | 51K | $10.73 | $551K | 1.3M |
| 2025-12-05 | AKKARAJU SRINIVAS | Director | Buy | 70K | $10.01 | $701K | 1.2M |
| 2025-12-05 | AKKARAJU SRINIVAS | Director | Buy | 65K | $8.95 | $581K | 1.1M |
| 2025-12-04 | AKKARAJU SRINIVAS | Director | Buy | 66K | $8.18 | $540K | 1.1M |
| 2025-12-03 | AKKARAJU SRINIVAS | Director | Buy | 100K | $7.75 | $775K | 1.0M |
| 2025-12-02 | AKKARAJU SRINIVAS | Director | Buy | 96K | $7.55 | $725K | 913K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON1 Form 144 notice on file for ALMS worth $140K at the prices reported; 0 in the last 90 days worth $0. Latest: SANAMPREET PANGALI filed on 2026-07-06 to sell 5,000 shares ($140K) from 2026-07-06.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-07-06 | SANAMPREET PANGALIOfficer | 5K | $140K | 0.004% | 2026-07-06 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON14 holders report 5% or more of ALMS in their latest filing, 8 on Schedule 13D (active intent). The largest reported stake is James B. Tananbaum at 14.5% of the class (9,181,328 shares), filed 2026-08-17 for an event on 2026-08-10.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-17 | 13D | James B. Tananbaumindividual | 9.2M | 14.5% | 2026-08-10 |
| 2026-08-17 | 13D | Foresite Capital Fund V, L.P.partnership | 3.6M | 5.6% | 2026-08-10 |
| 2026-08-17 | 13D | Foresite Capital Management V, LLCother entity | 3.6M | 5.6% | 2026-08-10 |
| 2026-08-17 | 13D | Foresite Capital Opportunity Fund V, L.P.partnership | 3.4M | 5.4% | 2026-08-10 |
| 2026-08-17 | 13D | Foresite Capital Opportunity Management V, LLCother entity | 3.4M | 5.4% | 2026-08-10 |
| 2026-08-17 | 13D | Foresite Capital Management VI, LLCother entity | 2.2M | 3.5% | 2026-08-10 |
| 2026-08-17 | 13D | Foresite Capital Fund VI LPpartnership | 2.2M | 3.5% | 2026-08-10 |
| 2026-08-06 | 13G | FMR LLCparent holding company | 6.8M | 5.5% | 2026-06-30 |
| 2026-08-06 | 13G | Abigail P. Johnsonindividual | 6.8M | 5.5% | 2026-06-30 |
| 2026-07-27 | 13G | BlackRock, Inc.parent holding company | 7.1M | 5.7% | 2026-06-30 |
| 2026-07-02 | 13D/Ano. 3 | David E. Goelindividual, parent holding company | 15.1M | 12.3% | 2026-05-14 |
| 2026-07-02 | 13D/Ano. 3 | AyurMaya Capital Management Company, LPinvestment adviser, partnership | 15.1M | 12.3% | 2026-05-14 |
| 2026-04-07 | 13G | Deep Track Capital, LPinvestment adviser, other entity | 7.4M | 6.0% | 2026-03-30 |
| 2026-04-07 | 13G | Deep Track Biotechnology Master Fund, Ltd.corporation | 7.4M | 6.0% | 2026-03-30 |
| 2026-04-07 | 13G | David Kroinparent holding company, individual | 7.4M | 6.0% | 2026-03-30 |
| 2026-04-03 | 13D/Ano. 4 | Foresite Labs Fund I, L.P.partnership | 2.0M | 1.6% | 2026-04-01 |
| 2026-04-03 | 13D/Ano. 4 | Foresite Labs Management I, LLCother entity | 2.0M | 1.6% | 2026-04-01 |
| 2026-04-03 | 13D/Ano. 4 | Labs Co-Invest V, LLCother entity | 194K | 0.2% | 2026-04-01 |
| 2026-04-03 | 13D/Ano. 4 | Foresite Labs, LLCother entity | 0 | 0.0% | 2026-04-01 |
| 2026-04-03 | 13D/Ano. 4 | Foresite Labs Affiliates 2021, LLCother entity | 0 | 0.0% | 2026-04-01 |
| 2026-01-13 | 13D/Ano. 1 | Srinivas Akkarajuindividual | 6.3M | 5.4% | 2026-01-09 |
| 2026-01-13 | 13D/Ano. 1 | Samsara BioCapital GP, LLCother entity | 4.5M | 3.8% | 2026-01-09 |
| 2026-01-13 | 13D/Ano. 1 | Samsara BioCapital, L.P.partnership | 4.5M | 3.8% | 2026-01-09 |
| 2026-01-13 | 13D/Ano. 1 | Samsara Opportunity Fund GP, LLCother entity | 1.9M | 1.6% | 2026-01-09 |
| 2026-01-13 | 13D/Ano. 1 | Samsara Opportunity Fund, L.P.partnership | 1.9M | 1.6% | 2026-01-09 |
| 2025-11-17 | 13G/Ano. 1 | GOODMAN COREY Sindividual, parent holding company | 4.6M | 4.8% | 2025-06-30 |
| 2025-11-17 | 13G/Ano. 1 | venBio Global Strategic Fund IV, L.P.partnership | 4.6M | 4.8% | 2025-06-30 |
| 2025-11-17 | 13G/Ano. 1 | venBio Global Strategic GP IV, LLCother entity, parent holding company | 4.6M | 4.8% | 2025-06-30 |
| 2025-11-17 | 13G/Ano. 1 | Adelman Robert Jindividual, parent holding company | 4.6M | 4.8% | 2025-06-30 |
13F holders
Tracked managers holding ALMS at their latest 13F. JSON5 of the 30 tracked managers held ALMS at their latest 13F, $61.2M in total at quarter-end prices. D. E. Shaw & Co. is the largest at $27.2M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 3 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| D. E. Shaw & Co. | 2026-06-30 | 968K | $27.2M | 0.01% | +396K |
| Millennium Management | 2026-06-30 | 660K | $18.6M | 0.01% | +54K |
| Two Sigma Investments | 2026-06-30 | 376K | $10.6M | 0.01% | -282K |
| AQR Capital Management | 2026-06-30 | 146K | $4.1M | 0.00% | -245 |
| Renaissance Technologies | 2026-06-30 | 23K | $657K | 0.00% | -52K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Alumis in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Alumis (ALMS), SEC CIK 1847367, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-09-30.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-09.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-08.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-07-06.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-17.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-05-14.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-08.JSON and CSV
- Company record
- EDGAR filing index for CIK 1847367Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
- UTHRUnited Therapeutics
- CPIXCumberland Pharmaceuticals
- REGNRegeneron Pharmaceuticals
- LLYEli Lilly
- VRTXVertex Pharmaceuticals
- ALNYAlnylam Pharmaceuticals
- CYTKCytokinetics
- BMYBristol Myers Squibb
- PTCTPTC Therapeutics
- INSMInsmed
- MDGLMadrigal Pharmaceuticals
- CORTCorcept Therapeutics
- IONSIonis Pharmaceuticals
- SDGRSchrodinger
- ROIVRoivant Sciences
- JNJJohnson & Johnson
- OPKOpko Health
- ALKSAlkermes
- ABBVAbbVie
- ABTAbbott Laboratories
- KNSAKiniksa Pharmaceuticals International
- BBIOBridgeBio Pharma
- ZTSZoetis
- JAZZJazz Pharmaceuticals
Datasets
Frequently Asked Questions
How much of ALMS is sold short?
What is ALMS's daily short volume?
Does ALMS have fails to deliver?
Are ALMS insiders buying or selling?
Have ALMS insiders filed to sell?
Who owns 5% or more of ALMS?
Which tracked 13F managers own ALMS?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.